Patent: 8,551,942

Summary for Patent: 8,551,942

Title:	Lyophilized anti-fungal compositions
Abstract:	A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature T.sub.g(s) of at least about 90.degree. C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature T.sub.g(c) of at least about 55.degree. C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.
Inventor(s):	Mittal; Sachin (Bridgewater, NJ), Jahansouz; Hossain (Burlingame, CA), Sottivirat; Sutthilug (Lansdale, PA)
Assignee:	Merck Sharp & Dohme, Corp. (Rahway, NJ)
Application Number:	13/628,592
Patent Claims:	see list of patent claims

United States Patent 8,551,942: Critical Claim Validity, Scope, and US Patent Landscape

What does US 8,551,942 claim, in enforceable terms?

US 8,551,942 claims a lyophilized (freeze-dried) antifungal composition whose distinguishing technical core is the combination of: (1) caspofungin (or salt), (2) trehalose as the non-reducing sugar, (3) an acetate buffer that sets pH 5 to 7, and (4) very low moisture plus specified glass transition temperature (Tg) targets.

Core composition claim (Claim 1) elements

Claim 1 requires all of the following simultaneously:

1. Active

   • Caspofungin or pharmaceutically acceptable salt in an effective amount.

2. Stabilizer sugar

   • One or more non-reducing sugars with Tg(s) ≥ 90°C.
   • Trehalose is the non-reducing sugar (explicitly limited).

3. Buffer/pH

   • Acetate buffer in an amount effective to provide pH 5 to 7.

4. Quantitative ratios

   • Trehalose : caspofungin (weight ratio) = 1.1:1 to 10:1.

5. Moisture and Tg of the dried matrix

   • Moisture content ≤ ~0.8 wt.%
   • Tg(c) ≥ ~55°C

Dependent claim “tightenings” (Claims 2-6)

These create a narrower sub-scope within the broader concept:

• Claim 2: moisture ≤ 0.5 wt.% and Tg(c) ≥ 90°C.
• Claims 3-4 (process link): lyophilization from an aqueous solution with defined concentration ranges.
• Claim 3 solution ranges
  • Caspofungin concentration: 5 mg/mL to 200 mg/mL
  • Sugar ratio (mg/mL basis): 2:1 to 10:1 (trehalose as the sugar later limited in Claim 4)
  • Acetate buffer: 12.5 mM to 200 mM
• Claims 5-6 (narrow formulation window)
  • Caspofungin: 30 mg/mL to 50 mg/mL
  • Trehalose : caspofungin: 4:1 to 8:1
  • Acetate buffer: 20 mM to 60 mM
  • Claim 6 also specifies trehalose absolute concentration: 180 mg/mL to 300 mg/mL

Process claims (Claims 7-12)

Claim 7 is a process claim that effectively repackages the formulation constraints into manufacturing logic:

• Prepare aqueous solution with:
  • pH 5-7
  • trehalose (non-reducing sugar) with Tg(s) ≥ 90°C
  • sugar-to-caspofungin ratio 1.1:1 to 10:1
  • acetate buffer
• Freeze-dry to yield moisture < 0.8 wt.%
• The resulting lyophilized product must have Tg(c) ≥ 55°C.

Claim 8 further constrains solution preparation steps:

• Dissolve trehalose
• Add acetic acid then adjust pH to 4.5 to 5.5 using base
• Add caspofungin/salt then adjust pH to 5 to 7 using base
• Optional filtration

Claims 9-11 constrain aqueous concentrations and moisture. Claim 12 is product-by-process for the lyophilized composition prepared under Claim 7.

Post-reconstitution and use claims (Claims 13-27)

These extend beyond the freeze-dried matrix:

• Kits (Claims 13 and 21):

  • Lyophilized composition in container + reconstitution solvent in second container.

• Reconstitution + dilution (Claims 14-18, 22-26):

  • Reconstitute to form concentrate; mix with diluent (including specific saline and sterile water options; and specific diluent strengths).
  • Concentrate caspofungin: 5 to 8 mg/mL
  • Final diluted formulation: 0.2 to 0.5 mg/mL

• Treatment/prophylaxis (Claim 20):

  • Parenteral administration of the liquid dosage formulation to treat or prevent fungal infection.

Enforceability focus: The litigation-relevant boundaries will be the parameter thresholds (moisture, Tg(c), sugar-to-drug ratio, acetate pH window) and the functional composition requirements (trehalose as the non-reducing sugar; acetate buffer; lyophilized antifungal).

Where is the patent landscape most crowded: trehalose, lyophilization, and Tg/matrix stabilization?

At a landscape level, the underlying technology themes are well-trodden:

• Lyophilization with stabilizers is a mature field.
• Trehalose is a common non-reducing sugar excipient used to stabilize biologics during freeze-drying and storage.
• Moisture control is a standard stabilization strategy because residual water depresses Tg and can accelerate degradation.
• Tg-based excipient selection and use of glass-formers to stabilize solid dosage forms is also common.

So, the defensibility does not rest on the generic use of trehalose or generic freeze-drying. It rests on whether US 8,551,942’s specific combination and numeric constraints (especially moisture and Tg thresholds, sugar/drug ratios, and acetate buffer pH 5-7) represent a non-obvious, patentable step over prior art.

The “narrowest differentiators” inside the claims

From a freedom-to-operate (FTO) perspective, these elements are the likely differentiators that attackers must overcome:

1. Trehalose is mandatory

   • Even though Claim 1 says “one or more non-reducing sugars,” it then explicitly states “trehalose is the non-reducing sugar.”

2. Trehalose : caspofungin weight ratio 1.1:1 to 10:1

   • If prior art uses trehalose but outside this window, the numeric limit becomes a key barrier to invalidity-by-mapping.

3. Residual moisture ≤ 0.8 wt.% (and ≤0.5 wt.% in Claim 2)

   • Many lyophilized products can have residual moisture above these thresholds depending on cycle, formulation, and stop criteria.

4. Tg(c) ≥ 55°C (and ≥ 90°C in Claim 2)

   • A prior art product might use trehalose but have a different Tg(c). If Tg(c is not disclosed and can’t be inferred, it becomes a factual/technical gap.

5. Acetate buffer at pH 5-7

   • Buffer identity and pH are not always tightly specified in older trehalose lyophilization disclosures.

6. Freeze-drying from aqueous solution with defined concentration ranges

   • Claims 3-6 and 7-11 lock in not only the solid-state targets but also the solution recipe ranges used to make them.

What do these claims leave exposed? (Key invalidity and non-infringement angles)

The patent’s risk profile is tied to two things: whether prior art already taught the same trehalose + acetate + pH + ratio + moisture + Tg targets for caspofungin, and whether the Tg/multivariate constraints are actually distinguishable in practice.

Likely vulnerability: “obvious to try” trehalose lyophilization

A challenger would argue that once trehalose is a known lyoprotectant, routine formulation development would optimize ratios and buffer/pH for stability. The patent counters this only if the numeric thresholds and Tg outcomes are shown to be non-obvious and not the result of ordinary experimentation.

Likely vulnerability: lack of structural novelty beyond excipient selection and process tuning

The claims do not require a unique solid-state morphology, specific crystalline form, or unique excipient interactions beyond the compositional recipe and Tg/moisture metrics.

If prior art already discloses:

• caspofungin lyophilized with trehalose,
• in acetate buffer,
• with pH in the claimed range,
• and yields similar moisture and Tg targets,

then the novelty collapses quickly.

Likely vulnerability: Tg and Tg(s) thresholds depend on measurement and interpretation

Even if the claims demand Tg(c) and Tg(s), prior art could report different Tg values depending on:

• DSC method, scan rate, and baseline treatment,
• water content assumptions,
• sample equilibration conditions.

A challenger can attempt to show that a prior art Tg measurement falls within the claimed thresholds under reasonable measurement conditions or that the relationship between moisture and Tg is predictable.

Non-infringement opportunities for competitors

From a design-around perspective, competitors can focus on any single limiting requirement:

• Use a buffer that is not acetate (e.g., phosphate or histidine-based systems).
• Use trehalose but set trehalose:caspofungin ratio outside 1.1:1 to 10:1.
• Use trehalose but target moisture >0.8 wt.% or Tg(c) <55°C.
• Use trehalose but in combination with other non-reducing sugars only if the claim is interpreted to still require trehalose as the non-reducing sugar (trehalose is mandatory, so mixing likely does not avoid infringement if trehalose is present; but the weight ratio limit could be used).
• For method/process claims, shift the recipe concentration ranges (Claims 3-6, 8-11) and/or avoid the exact freeze-drying outcome moisture target.

How strong is the claims’ coverage across the lifecycle (lyophilized product, reconstitution, dosing)?

Coverage splits into two tiers.

Tier 1: solid matrix formulation and manufacturing (Claims 1-12)

This is the tight, chemistry-heavy part. It will be the main battleground because it is the most likely to map to prior art disclosures and requires matching of physical parameters (moisture/Tg).

Tier 2: reconstitution and clinical administration logistics (Claims 13-27)

These claims largely track common reconstitution and dilution practices: reconstitute, then dilute with saline or sterile water/lactated ringer’s to reach a targeted concentration range.

Competitors may already use broadly similar reconstitution methods for caspofungin products. If such methods are widely used in marketed drug products or prior patents, these dependent claims may be easier to attack for obviousness or for lack of novelty.

US patent landscape: what matters most for freedom to operate and for invalidity mapping

Without an enumerated list of all cited prior art documents for US 8,551,942, the most actionable landscape analysis is to identify where patents typically cluster for this kind of subject matter:

Cluster A: lyophilized biologics with trehalose and controlled residual moisture

Patents in this cluster tend to claim:

• trehalose (or mixtures including trehalose),
• freeze-drying,
• residual moisture targets,
• Tg targets or glass-former theory.

Relevance to US 8,551,942: These patents can supply generic anticipation/obviousness unless they also specify caspofungin + acetate pH 5-7 + the sugar ratio window + Tg(c).

Cluster B: buffer systems for lyophilized peptides/antifungals

Patents in this cluster tend to specify:

• acetate vs phosphate vs citrate,
• pH 4-7 windows,
• ionic strength and stability.

Relevance: US 8,551,942 limits acetate buffer to pH 5-7; prior patents using acetate may still be very close.

Cluster C: Tg measurement and formulation design rules

Patents in this cluster cover:

• Tg(s) and Tg(c),
• moisture-Tg relationships,
• how to select sugars based on Tg(s) and achieve a stable glass.

Relevance: These can render Tg-threshold claims obvious even if the exact caspofungin composition is not disclosed, depending on how directly they connect Tg(s) selection to a specific sugar ratio and buffer system.

Cluster D: caspofungin-specific formulation patents

This is the most probative cluster. If any prior art caspofungin lyophilized patents exist with:

• trehalose,
• acetate buffer pH 5-7,
• and moisture/Tg targets in the same bands,

then the landscape becomes crowded in the exact claim space.

Practical takeaway: In litigation or FTO analysis, you prioritize caspofungin-specific patents first, then cascade to general trehalose lyophilization patents only if caspofungin-specific ones do not provide full parameter mapping.

How to interpret the claim architecture for litigation and deal-making

US 8,551,942 has a layered structure that can be used in both enforcement and defensive invalidity:

• Claim 1 establishes broad coverage around the combination of excipient type, ratio, pH, moisture, and Tg.
• Claims 2, 4, 5, 6 create narrower “best-in-class” embodiments with higher Tg(c) and more tightly specified concentrations.
• Claims 3-6 tie the final solid to a specific aqueous recipe range. This can help enforcement if manufacturing evidence shows the exact ranges were used, but it also gives competitors more levers to design around by changing the recipe.
• Process Claim 7 and dependent steps (Claim 8) create another enforcement hook based on manufacturing method and pH adjustment sequence.
• Claims 14-20 and 22-27 create downstream coverage for reconstitution and dosing concentration ranges, but these might be more vulnerable due to common practice.

Key Takeaways

• US 8,551,942’s enforceable differentiators are the numeric constraints: trehalose mandatory, trehalose:caspofungin 1.1:1 to 10:1, acetate pH 5-7, moisture ≤0.8 wt.% (and ≤0.5 wt.% in narrower claims), and Tg(c) ≥55°C (and ≥90°C in narrower claims).
• The patent’s technical core sits inside well-developed trehalose lyophilization and glass-former stabilization doctrines. The case for patentability depends on whether prior art already disclosed the same combination with matching Tg/moisture and acetate pH limits.
• For design-around, competitors can target a single limiting element: switch buffer away from acetate, shift the trehalose:drug ratio, allow higher residual moisture, or target a lower Tg(c).
• For enforcement, manufacturing evidence matters because multiple claims lock in solution concentration ranges and pH adjustment steps tied to freeze-drying outcomes.

FAQs

1) Which claim provides the broadest product coverage?
Claim 1 is the broadest formulation claim because it covers the trehalose-ace­tate-pH system with moisture and Tg(c) thresholds, without limiting the solution recipe to a narrow caspofungin concentration band.

2) What is the main narrow embodiment used to strengthen validity?
Claims 2 and 5-6 tighten moisture and Tg(c) and restrict solution concentrations, reducing the likelihood that a prior art formulation accidentally falls within the claim set.

3) Does the patent require trehalose alone or trehalose as part of a mixture?
It requires trehalose as “the non-reducing sugar,” so trehalose must be present. The claim text does not prohibit other non-reducing sugars conceptually, but trehalose is a required component.

4) What are the strongest design-around levers?
Residual moisture target, Tg(c), trehalose:caspofungin ratio, and acetate buffer/pH selection. Any one can break infringement.

5) Are the reconstitution and dosing claims likely to be easier to challenge?
They can be, because reconstitution to clinically typical caspofungin concentrations using saline/sterile water and common dilution steps can be widely practiced. Their novelty depends on how uniquely the concentration windows and kit logistics were claimed.

---

References

No sources were provided in the prompt for US Patent 8,551,942’s bibliographic record, specification, prosecution history, or cited references, so no external documents can be cited here.

Details for Patent 8,551,942

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	ZOSTAVAX	zoster vaccine live	For Injection	125123	May 25, 2006		2032-09-27